Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Microbiology and Immunology|January 1, 1985
Fatty acid composition and Shwartzman activity of lipopolysaccharides from oral bacteriaJ Mashimo, M Yoshida, K Ikeuchi, et al.Microbiology and Immunology|January 1, 1988
Structural heterogeneity regarding local Shwartzman activity of lipid AJ Mashimo, C Tanaka, S Arata, et al.Biochemical and Biophysical Research Communications|April 30, 1985
In vitro antigenic reactivity of synthetic lipid A analogues as determined by monoclonal and conventional antibodiesN Kasai, S Arata, J Mashimo, et al.Hepato-Gastroenterology|May 31, 2001
Risk factors for recurrence of large HCC in patients treated by combined TAE and PEIS Arata, K Tanaka, H Okazaki, et al.Human Molecular Genetics|February 13, 2001
Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activityY Sunada, H Ohi, A Hase, et al.Journal of Gastroenterology and Hepatology|December 1, 1996
Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trialK Tanaka, M Kondo, T Sakaguchi, et al.Infection and Immunity|January 1, 1986
Synthetic Salmonella-type lipid A antigen with high serological specificityN Kasai, S Arata, J Mashimo, et al.Animal Genetics|August 8, 2014
Evaluation of quantitative trait loci affecting intramuscular fat and reproductive traits in pigs using marker-assisted introgressionS Sato, C Ohnishi, T Kikuchi, et al.Nature Genetics|March 4, 2000
Rnx deficiency results in congenital central hypoventilationS Shirasawa, A Arata, H Onimaru, et al.Journal of Gastroenterology and Hepatology|March 1, 1996
Hepatic HCV-RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis CM Kondo, K Tanaka, M Ikeda, et al.Pageof 4